
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>Amlodipine</td><td>Fenofibrate</td><td>The metabolism of Fenofibrate can be decreased when combined with Amlodipine.</td></tr><tr><td>Amlodipine</td><td>Vortioxetine</td><td>The metabolism of Vortioxetine can be decreased when combined with Amlodipine.</td></tr><tr><td>Dolutegravir</td><td>Rosuvastatin</td><td>The excretion of Rosuvastatin can be decreased when combined with Dolutegravir.</td></tr><tr><td>Fenofibrate</td><td>Vortioxetine</td><td>The metabolism of Vortioxetine can be decreased when combined with Fenofibrate.</td></tr><tr><td>Lamivudine</td><td>Fenofibrate</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lamivudine is combined with Fenofibrate.</td></tr><tr><td>Lamivudine</td><td>Rosuvastatin</td><td>The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be
increased when Lamivudine is combined with Rosuvastatin.</td></tr><tr><td>Lamivudine</td><td>Vortioxetine</td><td>Lamivudine may decrease the excretion rate of Vortioxetine which could result in
a higher serum level.</td></tr><tr><td>Olmesartan</td><td>Fenofibrate</td><td>Olmesartan may decrease the excretion rate of Fenofibrate which could result in
a higher serum level.</td></tr><tr><td>Olmesartan</td><td>Silodosin</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Olmesartan is combined with Silodosin.</td></tr><tr><td>Olmesartan</td><td>Vortioxetine</td><td>Vortioxetine may decrease the antihypertensive activities of Olmesartan.</td></tr><tr><td>Rosuvastatin</td><td>Vortioxetine</td><td>The metabolism of Vortioxetine can be decreased when combined with Rosuvastatin.</td></tr><tr><td>Silodosin</td><td>Amlodipine</td><td>The risk or severity of orthostatic hypotension and dizziness can be increased
when Amlodipine is combined with Silodosin.</td></tr><tr><td>Silodosin</td><td>Dolutegravir</td><td>The serum concentration of Dolutegravir can be increased when it is combined
with Silodosin.</td></tr><tr><td>Silodosin</td><td>Umeclidinium</td><td>The serum concentration of Umeclidinium can be increased when it is combined
with Silodosin.</td></tr><tr><td>Umeclidinium</td><td>Dolutegravir</td><td>The serum concentration of Umeclidinium can be increased when it is combined
with Dolutegravir.</td></tr><tr><td>Umeclidinium</td><td>Vortioxetine</td><td>The metabolism of Umeclidinium can be decreased when combined with Vortioxetine.</td></tr></tbody></table></div>
